Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM.

Int J Clin Pharmacol Ther. 2010 May;48(5):297-308.

PMID:
20420786
2.

A review of infliximab use in ulcerative colitis.

Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

Clin Ther. 2008 Feb;30(2):223-30. doi: 10.1016/j.clinthera.2008.02.014. Review.

PMID:
18343261
3.

Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.

Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM.

Clin Ther. 2011 Jul;33(7):946-64. doi: 10.1016/j.clinthera.2011.06.002. Epub 2011 Jul 7.

PMID:
21741088
4.

Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.

Adedokun OJ, Sandborn WJ, Feagan BG, Rutgeerts P, Xu Z, Marano CW, Johanns J, Zhou H, Davis HM, Cornillie F, Reinisch W.

Gastroenterology. 2014 Dec;147(6):1296-1307.e5. doi: 10.1053/j.gastro.2014.08.035. Epub 2014 Aug 28.

5.

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis.

Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H.

Eur J Clin Pharmacol. 2009 Dec;65(12):1211-28. doi: 10.1007/s00228-009-0718-4. Epub 2009 Sep 16.

6.

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Danielsson A, Verbaan H, Hellström PM, Magnuson A, Curman B.

Gastroenterology. 2005 Jun;128(7):1805-11.

PMID:
15940615
7.

The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients.

Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB.

Am J Gastroenterol. 2007 Apr;102(4):794-802. Epub 2007 Feb 23. Erratum in: Am J Gastroenterol. 2007 Jun;102(6):1338.

PMID:
17324131
8.

A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.

Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, Boulton-Jones R, Williams A, Church N, Satsangi J, Arnott ID; Scottish Society of Gastroenterology Infliximab Group.

Aliment Pharmacol Ther. 2007 Aug 1;26(3):411-9.

9.

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, Podolsky DK.

Inflamm Bowel Dis. 2001 May;7(2):83-8.

PMID:
11383595
10.

Serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease of different disease activities.

Philipsen EK, Bondesen S, Andersen J, Larsen S.

Scand J Gastroenterol. 1995 Jan;30(1):50-3.

PMID:
7701250
11.

Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.

Adedokun OJ, Xu Z, Padgett L, Blank M, Johanns J, Griffiths A, Ford J, Zhou H, Guzzo C, Davis HM, Hyams J.

Inflamm Bowel Dis. 2013 Dec;19(13):2753-62. doi: 10.1097/01.MIB.0000435438.84365.f7.

PMID:
24193155
12.

Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients.

Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M.

Dig Liver Dis. 2002 Sep;34(9):626-30.

PMID:
12405248
13.

Colectomy rate in acute severe ulcerative colitis in the infliximab era.

Aratari A, Papi C, Clemente V, Moretti A, Luchetti R, Koch M, Capurso L, Caprilli R.

Dig Liver Dis. 2008 Oct;40(10):821-6. doi: 10.1016/j.dld.2008.03.014. Epub 2008 May 9.

PMID:
18472316
14.

An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.

Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G.

Ther Drug Monit. 2006 Apr;28(2):169-74.

PMID:
16628126
15.

Infliximab as a rescue therapy for hospitalized patients with severe ulcerative colitis refractory to systemic corticosteroids.

Yamamoto-Furusho JK, Uzcanga LF.

Dig Surg. 2008;25(5):383-6. doi: 10.1159/000170882. Epub 2008 Nov 13.

PMID:
19005257
16.

Infliximab for treatment of steroid-refractory ulcerative colitis.

Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M.

Dig Liver Dis. 2002 Sep;34(9):631-4.

PMID:
12405249
17.

Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.

Thukral C, Cheifetz A, Peppercorn MA.

Drugs. 2006;66(16):2059-65. Review.

PMID:
17112300
18.

Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.

Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, Bathon J.

Semin Arthritis Rheum. 2009 Oct;39(2):123-31. doi: 10.1016/j.semarthrit.2008.08.002. Epub 2008 Sep 27. Review.

PMID:
18823645
19.

Infliximab in the treatment of steroid-dependent ulcerative colitis.

Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A.

Eur Rev Med Pharmacol Sci. 2004 Sep-Oct;8(5):231-3.

PMID:
15638236
20.

Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study.

Ochsenkühn T, Sackmann M, Göke B.

Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1167-71.

PMID:
15489577

Supplemental Content

Support Center